Viral Hepatitis Vaccines, Hepatitis A, Cytomegalovirus, Varicella-Zoster Virus, Bordetella Pertussis Infection, Herpes Simplex (1 and 2)
Conditions
Brief summary
The purpose of this study is to determine the seroprevalence of Hepatitis A Virus (HAV), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Herpes Simplex (HSV) and Bordetella pertussis (BP)infections in Mexico.
Detailed description
In order to document the epidemiological changes in the sero-prevalence of Hepatitis A, Human simplex virus (1 and 2), Varicella-Zoster virus and Cytomegalovirus infections, we propose to conduct a population based, seroprevalence, cross-sectional study, in Mexico. This will allow the identification of susceptible populations, which in turn, will serve as evidence for the elaboration of recommendations for the prevention of Hepatitis A, Human simplex virus, Varicella-Zoster virus and Cytomegalovirus infection in the region. This study was conducted using data and serum samples from a random sample of subjects that participated in the 2006 National Health and Nutrition Survey.
Interventions
OTHERSerum sample
Serum samples collected
Sponsors
GlaxoSmithKline
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
• Previously enrolled subjects aged \>= 1 to 70 years for National Health and Nutrition Survey 2006 in Mexico, with previously obtained informed consent
Exclusion criteria
* Information required for the study is not available or incomplete. * Inadequate or insufficient serum sample to detect viral agents required for the study. * Serum sample wrongly identified.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-HAV seropositivity status: Subjects with anti-HAV antibody titers >= assay cut-off. | 6 to 10 months from study initiation |
| Anti-Pertussis Toxin seropositivity status for IgG and IgA: Subjects with anti-Pertussis Toxin antibody titers >= assay cut-off for IgG, Subjects with anti-Pertussis Toxin antibody titers >= assay cut-off for IgA | 6 to 10 months from study initiation |
| Anti-VZV seropositivity status: Subjects with anti-VZV antibody titers >= assay cut-off | 6 to 10 months from study initiation |
| Anti-CMV seropositivity status: Subjects with anti-CMV antibody titers >= assay cut-off | 6 to 10 months from study initiation |
| Anti-HSV seropositivity status (defined as the percentage of subjects with anti-HSV 1 and 2 titers >= assay cut-off): Subjects with anti-HSV antibody titers >= assay cut-off | 6 to 10 months from study initiation |
Secondary
| Measure | Time frame |
|---|---|
| Difference in HAV, VZV, CMV , HSV and BP seropositivity rates according to socioeconomic status, age group, gender, region, risk group, area and pertussis vaccination status (only for BP analysis) | 6 to 10 months from study initiation |
Countries
Mexico
Outcome results
None listed